primary ciliary dyskinesia pcd pipeline insight

DelveInsight’s, “Primary Ciliary Dyskinesia Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary Ciliary Dyskinesia Understanding

Primary Ciliary Dyskinesia Overview

Primary ciliary dyskinesia (PCD) is a rare, inherited, autosomal recessive disorder characterized by structural and functional abnormalities of motile cilia microscopic, hair-like organelles lining the respiratory tract, sinuses, middle ear, and reproductive system. These cilia play a critical role in clearing mucus, pathogens, and debris from the airways through coordinated beating. In PCD, genetic mutations affecting ciliary proteins lead to impaired or absent ciliary motility, resulting in defective mucociliary clearance. Fertility may also be affected, particularly in males, due to impaired flagellar motility of sperm. 

PCD is characterized by chronic respiratory symptoms beginning early in life, including a persistent wet cough, recurrent lung infections, and chronic nasal congestion or sinusitis due to impaired mucus clearance. Patients often experience frequent ear infections, which may affect hearing, and some newborns present with respiratory distress at birth. About half of individuals have organ laterality defects (e.g., situs inversus), and some may develop reduced fertility later in life. 
PCD is caused by genetic defects affecting the structure and function of motile cilia, with pathogenic variants identified in more than 50 genes involved in ciliary assembly and movement. These mutations disrupt key components such as dynein arms, radial spokes, and microtubules, leading to impaired or absent ciliary beating and defective mucociliary clearance. As a result, mucus and pathogens accumulate in the respiratory tract, driving chronic infections and inflammation. PCD is most commonly inherited in an autosomal recessive manner, although some forms follow autosomal dominant (e.g., FOXJ1, TUBB4B) or X-linked (e.g., DNAAF6, OFD1, RPGR) inheritance patterns. Notably, around 20-30% of clinically diagnosed cases lack an identifiable genetic mutation, indicating additional undiscovered mechanisms. 

Diagnosis and treatment of primary ciliary dyskinesia involve a combination of genetic, functional, and supportive clinical approaches. Diagnosis is primarily confirmed through molecular genetic testing, identifying pathogenic variants in PCD-associated genes via multigene panels or comprehensive genomic sequencing. This is supported by functional tests such as low nasal nitric oxide levels, ciliary ultrastructural analysis using electron microscopy, and assessment of ciliary motility. Additional evaluations help determine disease severity, including imaging, lung function tests, and infection profiling.
Currently, there are no curative therapies for PCD treatment focuses on managing symptoms and preventing complications. This includes airway clearance techniques (e.g., chest physiotherapy), prompt and targeted antibiotic therapy for infections, and routine immunizations to reduce respiratory risk. Patients with frequent exacerbations may benefit from chronic macrolide therapy, while advanced cases may require interventions such as surgery or lung transplantation. Management also addresses associated conditions like sinus disease, hearing impairment, and fertility issues, with a multidisciplinary approach aimed at preserving lung function and improving quality of life.

"Primary Ciliary Dyskinesia Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Ciliary Dyskinesia pipeline landscape is provided which includes the disease overview and Primary Ciliary Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Primary Ciliary Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Ciliary Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Primary Ciliary Dyskinesia Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Primary Ciliary Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Primary Ciliary Dyskinesia.

Primary Ciliary Dyskinesia Emerging Drugs Analysis

This segment of the Primary Ciliary Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Ciliary Dyskinesia Emerging Drugs

RCT1100: ReCode Therapeutics

RCT1100 is an investigational, inhaled mRNA-based therapy developed by ReCode Therapeutics to treat primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations. Using a specialized lipid nanoparticle (LNP) delivery system, it aims to restore proper ciliary function. By giving RCT1100 (DNAI1-mRNA) as an inhaled therapy to people with PCD caused by this missing gene, it may be possible to restore ciliary function in the lungs, getting at the root cause of PCD rather than just symptom control. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Primary Ciliary Dyskinesia.

Further product details are provided in the report……..

Primary Ciliary Dyskinesia Drug Therapeutic Assessment

This segment of the report provides insights about the different Primary Ciliary Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:
Major  Players in Primary Ciliary Dyskinesia
There are approx. 5+ key companies which are developing the therapies for Primary Ciliary Dyskinesia. The companies which have their Primary Ciliary Dyskinesia drug candidates in the early stage, i.e. Phase I include, ReCode Therapeutics.

Primary Ciliary Dyskinesia Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Primary Ciliary Dyskinesia Drug Route of Administration

Primary Ciliary Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Primary Ciliary Dyskinesia Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Primary Ciliary Dyskinesia Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Ciliary Dyskinesia Clinical Trial Activities 

The Primary Ciliary Dyskinesia Pipeline report provides insights into different Primary Ciliary Dyskinesia Clinical Trials within phase II, I, preclinical and discovery stage. It also analyses Primary Ciliary Dyskinesia therapeutic drugs key players involved in developing key drugs. 

Primary Ciliary Dyskinesia Pipeline Development Activities

The Primary Ciliary Dyskinesia Clinical Trial report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Ciliary Dyskinesia drugs.

Primary Ciliary Dyskinesia Pipeline Report Insights

• Primary Ciliary Dyskinesia Pipeline Analysis
• Primary Ciliary Dyskinesia Therapeutic Assessment
• Primary Ciliary Dyskinesia Unmet Needs
• Impact of Primary Ciliary Dyskinesia Drugs

Primary Ciliary Dyskinesia Pipeline Report Assessment

• Primary Ciliary Dyskinesia Pipeline Product Profiles
• Primary Ciliary Dyskinesia Therapeutic Assessment
• Primary Ciliary Dyskinesia Pipeline Assessment
• Primary Ciliary Dyskinesia Inactive drugs assessment
• Primary Ciliary Dyskinesia Market Unmet Needs

Key Questions Answered in the Primary Ciliary Dyskinesia Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Primary Ciliary Dyskinesia drugs?
• How many Primary Ciliary Dyskinesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Ciliary Dyskinesia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Ciliary Dyskinesia therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Primary Ciliary Dyskinesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Primary Ciliary Dyskinesia Key Players

• ReCode Therapeutics
• Ethris

Primary Ciliary Dyskinesia Key Products

• RCT1100
• ETH42